Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05472506
Title Oral AHR Antagonist in Combination With Nivolumab in Patients With Resistant or Recurrent Head and Neck Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ikena Oncology
Indications

head and neck squamous cell carcinoma

Therapies

KYN-175 + Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.